Revolutionising healthcare with peptide-based therapies

BioPharma: Peptides are naturally occurring biological molecules built from our body’s amino acids. Peptides also represent a unique class of biopharmaceutical therapeutics, molecularly poised between small molecules and proteins, yet biochemically and therapeutically distinct from both. With expertise in peptide innovation, ImmuPharma is focused on delivering safe and efficacious peptide-based Bio-drugs through its Bordeaux subsidiary ImmuPharma Biotech.

Our focus and expertise within R&D are:

• Autoimmunity & Inflammation
• Anti-Infectives

Creation: Our principal mission is to craft a targeted and robust pipeline of efficient and safe compounds based on biopolymers: peptides. Our lead candidate, P140 (Lupuzor™), is advancing into Phase 3 for the treatment of systemic lupus erythematosus (SLE), and its unique mechanism of action heralds significant promise for therapeutic repositioning in the realm of autoimmune diseases.

Our team is also intensely focused on therapeutic upcycling, which strives to achieve considerable enhancements in existing therapies for specific diseases. This program leverages our ADMET (Chemical absorption, distribution, metabolism, excretion, and toxicity) programming technology to forge long-term shareholder value.

Evolution: necessitates a drive for positive transformation. Our inspirational and attainable goals include:

• Spearheading innovative R&D, targeted at commercially viable and attainable goals

• Aligning with expert collaborators for the development and commercialisation of our therapeutic products

• Developing a pipeline with depth and breadth to facilitate near and long term value, continuous news flow, and revenue generation